NVCR Novocure Ltd

USD 14.64 1.57 12.012242
Icon

Novocure Ltd (NVCR) Stock Analysis and Price Targets

COMMON STOCK | Medical Devices | NSD
stockTargetAdvisor

Hold

Average Analyst
Rating
stockTargetAdvisor

Hold

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 14.64

+1.57 (+12.01)%

USD 1.42B

0.01B

USD 19.63(+34.05%)

N/A

Icon

NVCR

Novocure Ltd (USD)
COMMON STOCK | NSD
USD 14.64
0.00 0
Take a Tour
stockTargetAdvisor

Hold

Average Analyst
Rating
stockTargetAdvisor

Hold

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 1.42B

N/A

USD 14.64

Novocure Ltd (NVCR) Stock Forecast

Show ratings and price targets of :
USD 19.63
(+34.05%)

Based on the Novocure Ltd stock forecast from 4 analysts, the average analyst target price for Novocure Ltd is USD 19.63 over the next 12 months. Novocure Ltd’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Novocure Ltd is Bearish, which is based on 1 positive signals and 7 negative signals. At the last closing, Novocure Ltd’s stock price was USD 14.64. Novocure Ltd’s stock price has changed by +7.41% over the past week, -10.18% over the past month and -74.88% over the last year.

No recent analyst target price found for Novocure Ltd
No recent average analyst rating found for Novocure Ltd

Company Overview Novocure Ltd

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFie...Read More

https://www.novocure.com

No. 4 The Forum, Saint Helier, Jersey, JE2 4UF

1,453

December

USD

USA

Adjusted Closing Price for Novocure Ltd (NVCR)

Loading...

Unadjusted Closing Price for Novocure Ltd (NVCR)

Loading...

Share Trading Volume for Novocure Ltd Shares

Loading...

Compare Performance of Novocure Ltd Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for NVCR

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Novocure Ltd (Sector: Medical Devices )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
DXCM
DexCom Inc -0.45 (-0.32%) USD51.34B 103.24 55.96

ETFs Containing NVCR

Symbol Name NVCR's Weight Expense Ratio Price(Change) Market Cap

Frequently Asked Questions About Novocure Ltd (NVCR) Stock

Based on ratings from 4 analysts Novocure Ltd's stock is Hold . Stock Target Advisor's fundamental analysis is Bearish. The stock has 1 buy, sell and 7 hold ratings.

Unfortunately we do not have enough data on NVCR's stock to indicate if its a good dividend stock.

Based on targets from 4 analysts, the average taret price for NVCR is USD 19.63 over the next 12 months. The maximum analyst target price is USD 24 while the minimum anlayst target price is USD 15.

NVCR stock's Price/Earning ratio is 1,480.87. Our analysis grades NVCR stock's Price / Earning ratio at F. This means that NVCR stock's Price/Earning ratio is above 98% of the stocks in the Medical Devices sector in the NSD exchange. Based on this NVCR may be a overvalued for its sector.

The last closing price of NVCR's stock was USD 14.64.

The most recent market capitalization for NVCR is USD 1.42B.

Based on targets from 4 analysts, the average taret price for NVCR is projected at USD 19.63 over the next 12 months. This means that NVCR's stock price may go up by +34.05% over the next 12 months.

We can't find any ETFs which contains Novocure Ltd's stock.

As per our most recent records Novocure Ltd has 1,453 Employees.

Novocure Ltd's registered address is No. 4 The Forum, Saint Helier, Jersey, JE2 4UF. You can get more information about it from Novocure Ltd's website at https://www.novocure.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...